166 related articles for article (PubMed ID: 37914764)
21. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of tumoral heterogeneity and volumetric parameters as measured by F18-FDG PET/CT in sinonasal cancer.
Kim BS; Pak K; Yi KI; Kim IJ; Roh HJ; Cho KS
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1437-1443. PubMed ID: 27747383
[TBL] [Abstract][Full Text] [Related]
23. The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring.
Yao Y; Zhou X; Zhang A; Ma X; Zhu H; Yang Z; Li N
Eur J Radiol; 2022 Apr; 149():110200. PubMed ID: 35158214
[TBL] [Abstract][Full Text] [Related]
24. Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach.
Dimitrakopoulou-Strauss A; Sachpekidis C; Hassel JC; Christopoulos P
Cancer Biother Radiopharm; 2023 May; 38(4):225-231. PubMed ID: 36961434
[TBL] [Abstract][Full Text] [Related]
25. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitor-Related Adverse Effects and
Schierz JH; Sarikaya I; Wollina U; Unger L; Sarikaya A
J Nucl Med Technol; 2021 Dec; 49(4):324-329. PubMed ID: 34330805
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V
Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
[TBL] [Abstract][Full Text] [Related]
28. Assessing the role of colonic and other anatomical sites uptake by [
Rizzo A; Cantale O; Mogavero A; Garetto L; Racca M; Venesio T; Anpalakhan S; Novello S; Gregorc V; Banna GL
Thorac Cancer; 2023 Aug; 14(24):2473-2483. PubMed ID: 37442801
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
van de Donk PP; Wind TT; Hooiveld-Noeken JS; van der Veen EL; Glaudemans AWJM; Diepstra A; Jalving M; de Vries EGE; de Vries EFJ; Hospers GAP
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4369-4376. PubMed ID: 34076745
[TBL] [Abstract][Full Text] [Related]
30. Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
Ren Y; Pan F; Kan X; Wang J; Han P; Yan J; Li L; Sun P; Liu CY; Bao Q; Yang L; Zheng C
Mol Pharm; 2022 Oct; 19(10):3664-3672. PubMed ID: 35976154
[TBL] [Abstract][Full Text] [Related]
31. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.
Xing X; Zhao Q; Zhou J; Zhou R; Liu Y; Qin X; Zhang M; Zhong Y; Wang J; Tian M; Zhang H
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1671-1688. PubMed ID: 36622406
[TBL] [Abstract][Full Text] [Related]
33. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
34. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
35.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
[TBL] [Abstract][Full Text] [Related]
37.
Workman AD; Glicksman JT; Parasher AK; Carey RM; Brooks SG; Kennedy DW; Nabavizadeh SA; Learned KO; Palmer JN; Adappa ND
Otolaryngol Head Neck Surg; 2017 Dec; 157(6):1068-1074. PubMed ID: 28809123
[TBL] [Abstract][Full Text] [Related]
38. Temporal patterns of
Schwartz JS; Brooks SG; Stubbs V; Ghosh A; Tajudeen BA; Khalili S; Palmer JN; Lee JY; Nabavizadeh SA; Learned KO; Adappa ND
Int Forum Allergy Rhinol; 2016 Dec; 6(12):1301-1307. PubMed ID: 27383662
[TBL] [Abstract][Full Text] [Related]
39. Hybrid positron emission tomography imaging for initial staging of sinonasal tumors: Total lesion glycolysis as prognosticator of treatment response.
Meerwein CM; Maurer A; Stolzmann P; Stadler TM; Soyka MB; Holzmann D; Hüllner MW
Head Neck; 2021 Jan; 43(1):238-246. PubMed ID: 32946188
[TBL] [Abstract][Full Text] [Related]
40. PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.
Gao Y; Wu C; Chen X; Ma L; Zhang X; Chen J; Liao X; Liu M
Front Immunol; 2022; 13():1049043. PubMed ID: 36341331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
